Multiple Myeloma Clinical Trial

Covid-19 Vaccine Responsiveness in MM and Waldenstrom

Summary

This research is being done to see if the immune (defense) system of people with Multiple Myeloma and Waldenstrom's Macroglobulinemia reacts to the COVID-19 vaccine.

View Full Description

Full Description

COVID-19 vaccines are designed to help prevent infections, hospitalizations, and death from the COVID-19 virus. Normally, when the vaccine is administered, the immune system reacts by creating antibodies (proteins made by the body's immune system to fight infections such as COVID-19) and helping the immune system's blood cells to fight it. In people with Multiple Myeloma and Waldenstrom's Macroglobulinemia, their immune system does not function normally, and an effective immune response may not occur. The research study procedures include screening for eligibility and the collection of data and biospecimens. It is expected that about 160 people will take part in this research study.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Age >18 years.
Lack of a contra-indication to a currently available COVID-19 vaccine.
Diagnosis of MM according to International Myeloma Working Group (IWMG) criteria (Cohort 1) or Diagnosis of WM according to WHO criteria (Cohort 2)

For treatment naïve WM patients (Cohort 2A):

Patient must have no prior history of anticancer treatment for WM.
The treating investigator must have no intention to initiate WM therapy within 2 months

For WM patients receiving BTK inhibitor (Cohort 2B):

Patient must have no history of cytotoxic chemotherapy within 1 year, and no history of other anticancer therapy within 6 months.

For currently or previously treated WM patients (Cohort 2C):

Patient must not be currently taking a BTK inhibitor or had recent exposure within 1 month of enrollment. Current or prior history of any other WM-directed therapy is allowed.

Exclusion Criteria:

-

Study is for people with:

Multiple Myeloma

Estimated Enrollment:

160

Study ID:

NCT04830046

Recruitment Status:

Not yet recruiting

Sponsor:

Massachusetts General Hospital

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There is 1 Location for this study

See Locations Near You

Brigham and Women's Hospital
Boston Massachusetts, 02215, United States More Info
Clifton Mo, MD
Contact
617-582-7969
[email protected]
Clifton Mo, MD
Principal Investigator
Dana-Farber Cancer Institute
Boston Massachusetts, 02215, United States More Info
Clifton Mo, MD
Contact
617-582-7969
[email protected]
Clifton Mo, MD
Principal Investigator

How clear is this clinincal trial information?

Study is for people with:

Multiple Myeloma

Estimated Enrollment:

160

Study ID:

NCT04830046

Recruitment Status:

Not yet recruiting

Sponsor:


Massachusetts General Hospital

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider